LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer - BioSpace

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer  BioSpace

AstraZeneca and Merck's LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for Patients Who ...



Comments

Popular posts from this blog

“63 Signs You May Have Long COVID | Eat This Not That - Eat This, Not That” plus 3 more

“Diagnosis and management of acute respiratory distress syndrome - CMAJ” plus 2 more